Anavex Life Sciences (AVXL) Total Liabilities (2010 - 2025)
Anavex Life Sciences recorded quarterly Total Liabilities of $6.4 million in Q4 2025, down 28.78% quarter-over-quarter from $8.9 million in Q3 2025, and down 51.47% year-over-year from $13.1 million in Q4 2024.
Anavex Life Sciences' Total Liabilities history runs 16 years deep, the most recent figure standing at $6.4 million for Q4 2025.
- In Q4 2025, Total Liabilities fell 51.47% year-over-year to $6.4 million; the TTM figure through Dec 2025 stood at $6.4 million (down 51.47% YoY), while the FY2025 annual figure was $8.9 million, down 41.54% from the prior year.
- Total Liabilities came in at $6.4 million for Q4 2025 at Anavex Life Sciences, down from $8.9 million in the prior quarter.
- In the past five years, Total Liabilities ranged from a high of $17.4 million in Q1 2025 to a low of $6.4 million in Q4 2025.
- A 5-year average of $11.2 million and a median of $10.9 million in 2021 frame the typical range for Total Liabilities.
- On a YoY basis, Total Liabilities climbed as much as 81.85% in 2025 and fell as far as 51.47% in 2025.
- Anavex Life Sciences' Total Liabilities stood at $10.5 million in 2021, then advanced by 25.83% to $13.2 million in 2022, then retreated by 5.68% to $12.5 million in 2023, then gained by 5.07% to $13.1 million in 2024, then sank by 51.47% to $6.4 million in 2025.
- According to Business Quant data, Total Liabilities over the past three periods registered $6.4 million, $8.9 million, and $11.5 million for Q4 2025, Q3 2025, and Q2 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 16.35 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 1.74 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 731.60 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 177.22 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 19.51 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 7.12 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | 10.44 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 9.45 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 4.05 Bn |
| 10 | Anavex Life Sciences | 266.20 Mn | 134.45 Mn | - | 6.37 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 6.37 Mn |
| Sep 30, 2025 | 8.95 Mn |
| Jun 30, 2025 | 11.47 Mn |
| Mar 31, 2025 | 17.38 Mn |
| Dec 31, 2024 | 13.13 Mn |
| Sep 30, 2024 | 15.30 Mn |
| Jun 30, 2024 | 11.75 Mn |
| Mar 31, 2024 | 9.56 Mn |
| Dec 31, 2023 | 12.50 Mn |
| Sep 30, 2023 | 12.53 Mn |
| Jun 30, 2023 | 11.06 Mn |
| Mar 31, 2023 | 14.02 Mn |
| Dec 31, 2022 | 13.25 Mn |
| Sep 30, 2022 | 10.21 Mn |
| Jun 30, 2022 | 9.48 Mn |
| Mar 31, 2022 | 8.07 Mn |
| Dec 31, 2021 | 10.53 Mn |
| Sep 30, 2021 | 10.80 Mn |
| Jun 30, 2021 | 9.27 Mn |
| Mar 31, 2021 | 7.76 Mn |
| Dec 31, 2020 | 8.03 Mn |
| Sep 30, 2020 | 7.31 Mn |
| Jun 30, 2020 | 6.95 Mn |
| Mar 31, 2020 | 6.23 Mn |
| Dec 31, 2019 | 5.46 Mn |
| Sep 30, 2019 | 5.04 Mn |
| Jun 30, 2019 | 779,414.00 |
| Mar 31, 2019 | 3.37 Mn |
| Dec 31, 2018 | 2.63 Mn |
| Sep 30, 2018 | 3.88 Mn |
| Jun 30, 2018 | 3.21 Mn |
| Mar 31, 2018 | 3.42 Mn |
| Dec 31, 2017 | 2.80 Mn |
| Sep 30, 2017 | 3.58 Mn |
| Jun 30, 2017 | 1.45 Mn |
| Sep 30, 2016 | 3.19 Mn |
| Sep 30, 2015 | -12.81 Mn |
| Jun 30, 2015 | 1.41 Mn |
| Mar 31, 2015 | 1.66 Mn |
| Dec 31, 2014 | 6.58 Mn |
| Sep 30, 2014 | 7.16 Mn |
| Jun 30, 2014 | 1.91 Mn |
| Mar 31, 2014 | 1.88 Mn |
| Dec 31, 2013 | 1.82 Mn |
| Sep 30, 2013 | 2.86 Mn |
| Jun 30, 2013 | 3.56 Mn |
| Mar 31, 2013 | 3.44 Mn |
| Dec 31, 2012 | 3.41 Mn |
| Sep 30, 2012 | 2.89 Mn |
| Jun 30, 2012 | 2.22 Mn |
| Mar 31, 2012 | 3.12 Mn |
| Sep 30, 2011 | 1.35 Mn |
| Sep 30, 2010 | 2.96 Mn |